Clinical Trials on Suspected or Documented Gram-negative Bacterial Infection

Total 4936 results

GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Belgium
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Infections, Meningococcal

United States
International Vaccine Institute
Shantha Biotechnics Limited; Armauer Hansen Research Institute, Ethiopia; Ministry...

Completed

Bridging Study for Killed Oral Cholera Vaccine in Ethiopia

Cholera | Vibrio Cholerae

Ethiopia
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Gonococcal Infection

United States
GlaxoSmithKline

Completed

Safety of 4CMenB Exposure During Pregnancy

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

Infections, Meningococcal

Germany, France
GlaxoSmithKline

Completed

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Infections, Meningococcal

Germany
GlaxoSmithKline

Completed

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Infections, Meningococcal

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Infections, Meningococcal

United States
University of Zurich

Unknown

Effects of Nutritional Fat on the Growth of Intestinal E. Coli

Escherichia Coli Infections

Switzerland
GlaxoSmithKline

Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Infections, Meningococcal

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

Infections, Meningococcal

Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Infections, Meningococcal

United States, Canada
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol

E Coli Infections

United States
GlaxoSmithKline

Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

Infections, Meningococcal

Austria, Greece
GlaxoSmithKline

Completed

Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration

Infections, Meningococcal

Taiwan, Mexico
GlaxoSmithKline

Completed

N. Meningitidis Carriage Study

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

Infections, Meningococcal

United States, Czechia
GlaxoSmithKline

Completed

Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Infections, Meningococcal

Denmark
Novartis

Completed

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

Pseudomonas Infections

Germany
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Meningococcal Disease

Korea, Republic of
Novartis Vaccines

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Meningococcal Disease

United States, Poland
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Italy
Jiangsu Province Centers for Disease Control and...
Lanzhou Institute of Biological Products Co., Ltd

Completed

Immunogenicity and Safety of Subunit Plague Vaccine

Plague

China
Novartis Vaccines

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Meningococcal Disease

Austria, Finland, Germany, Italy, Czech Republic
Leiden University Medical Center

Completed

Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines

Meningococcal Disease

Netherlands
Centers for Disease Control and Prevention
MRC/UVRI and LSHTM Uganda Research Unit; Ministry of Health, Uganda

Unknown

A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans

Plague

Uganda
Valneva Austria GmbH
Johns Hopkins University; Naval Medical Research Center

Completed

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

Diarrhea | Enterotoxigenic Escherichia Coli Infection

United States
Centre Hospitalier Universitaire, Amiens

Completed

Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates (CRY-NOT)

Ophthalmia Neonatorum

France
National Institute of Allergy and Infectious Diseases...

Completed

Experimental Human Infection With Neisseria Gonorrhoeae

Gonococcal Infection

United States
MerLion Pharmaceuticals GmbH

Completed

First Time in Man Study of Finafloxacin Hydrochloride

Urinary Tract Infection | Helicobacter Infections

Switzerland
Thomas Benfield

Recruiting

Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia (GNB5)

Urinary Tract Infection Bacterial | Gram-negative Bacteremia

Denmark
Poitiers University Hospital

Recruiting

Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease (CARACIIM)

Meningococcal Infections

France
Jiangsu Province Centers for Disease Control and...

Active, not recruiting

Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

Plague

China
GlaxoSmithKline

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

Plague

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Meningococcal Disease

Italy
Novartis Vaccines

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Meningococcal Disease

Finland, Czech Republic
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
London School of Hygiene and Tropical Medicine
Bill and Melinda Gates Foundation

Withdrawn

A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger (VES)

Meningococcal Disease

Mali, Niger
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

Shigella Infection

United States
Institut Pasteur

Completed

Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine

Shigella Infection

France, United Kingdom
Public Health England

Completed

PRIME Follow up - Quadri Meningo Vacinees (PRIMEfollowup)

Meningococcal Disease
University Hospital, Angers

Unknown

Factors Influencing the Fecal Relative Abundance of ESBL-producing Enterobacteriaceae in Intensive Care (BLSE-REA).

ESBL-producing Enterobacteriaceae Infections
University of Adelaide
SA Health

Completed

South Australian Meningococcal B Vaccine Herd Immunity Study (B Part of It)

Meningococcal Disease

Australia
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile

3

Subscribe